US lawmakers, drug makers weigh in on US biosimilars
This article was originally published in SRA
Executive Summary
Latest stakeholder comments to the US Food and Drug Administration on the best path forward for the entrance of biosimilars on to the US market show that debate on the matter is far from over1,2.